Signal transduction of somatostatin receptors negatively controlling cell proliferation
Introduction
Somatostatin acts on various targets including the brain, pituitary, pancreas, gut, adrenals, thyroid, kidney and immune system to regulate a variety of physiological functions. Its actions include inhibition of endocrine and exocrine secretions, modulation of neurotransmission, motor and cognitive functions, inhibition of intestinal motility, absorption of nutrients and ions, vascular contractility and cell proliferation. The biological effects of somatostatin are mediated via high affinity plasma membrane receptors which are widely distributed throughout many tissues ranging from the central nervous system to the pancreas and gut, and also in pituitary, kidney, thyroid, lung and immune cells [14], [23].
Due to the short half-life of natural somatostatin peptides, many somatostatin peptide analogues have been synthesised. Among them, octreotide (SMS 201-995), lanreotide (BIM 23014) and vapreotide (RC-160) are in clinical use for the medical treatment of acromegaly and neuroendocrine tumours.
Compelling evidence has implicated somatostatin in the inhibition of the growth and development of various normal and tumour cells. Thus, somatostatin analogues show antineoplastic activity in a variety of experimental models in vivo and in vitro [40], [50]. Somatostatin receptors are expressed in a large variety of human tumours and somatostatin analogue treatment induces the shrinkage of pituitary [29] and the stabilization of neuroendocrine tumour progression [3]. However, the clinical implications of the presence of somatostatin receptors in tumours for diagnostic and therapeutic purposes will need to define the physiological role of each receptor subtype expressed in the tumours with respect to its antisecretory and antiproliferative properties.
Section snippets
Somatostatin receptor family
To date, five receptors subtypes, sst1-sst5, have been cloned. Human sst subtypes are encoded by 5 genes localized on separate chromosomes. Four of these genes are intronless in their coding region, the exception being sst2 which is alternatively spliced in rodents to generate two isoforms named sst2A and sst2B which diverge in their C-terminal sequence. The sst subtypes belong to the family of G-protein coupled receptors with seven transmembrane spanning domains and present a high degree of
Indirect effects of somatostatin on cell growth
Indirect effects of somatostatin on tumour growth may be the result of inhibition of secretion of growth-promoting hormones and growth factors which stimulate the growth of various types of cancer. For example, insulin-like growth factor-1 (IGF-1) which is produced by hepatocytes through GH-dependent and -independent mechanisms is an important modulator of many neoplasms [25] and octreotide negatively controls serum IGF-1 level as a result of an effect on GH secretion, probably via sst2 and
Direct effect of somatostatin on cells
Somatostatin directly inhibits cell growth by interacting with specific somatostatin receptors located on target cells. Somatostatin receptors are present in various normal and cancer cells [31]. Analysis of sst mRNAs demonstrate that human tumours from neuroendocrine and gastroenteropancreatic origin, brain tumours (gliomas and meningiomas), prostate, lung and breast tumours express sst mRNA, each tumour expressing more than one subtype and sst2 being the most frequently expressed [31], [36].
Conclusion
The five somatostatin receptors can be involved in the growth inhibitory effect of somatostatin and analogues and this property may be relevant for the analogue therapy of tumours which express somatostatin receptors. However, most of studies of the antiproliferative effect of somatostatin receptor subtypes have been conducted in vitro, on recombinant cells. The development of specific antibodies, agonists and antagonists as well as gene knockout models will help to define in vivo, the role of
References (52)
- et al.
Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade
J. Biol. Chem.
(1994) - et al.
Sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1
J. Biol. Chem.
(1998) - et al.
Inhibition of L-type calcium channels by octreotide in isolated human neuroendocrine tumor cells of the gut
Biochem. Biophys. Res. Commun.
(1998) - et al.
Subtype-specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2
J. Biol. Chem.
(1994) - et al.
Coupling of rat somatostatin receptor subtypes to a G-protein gated inwardly rectifying potassium channel (GIRK1)
FEBS Lett.
(1997) - et al.
The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity
J. Biol. Chem.
(1994) - et al.
High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice
Gastroenterology
(1998) - et al.
Protein tyrosine phosphatases in signal transduction
Curr. Opin. Cell Biol.
(1997) - et al.
Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1
J. Biol. Chem.
(1999) - et al.
Molecular properties of somatostatin receptors
Neuroscience
(1995)
Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin
Neuron
A somatostatin receptor 1 selective ligand inhibits Ca2+ currents in rat insulinoma 1046-38 cells
FEBS Lett.
Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation
J. Biol. Chem.
Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20
Neuroscience
Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells
Cell Immunol.
Somatostatin analogs for diagnosis and treatment of cancer
Pharmacol. Ther.
Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis
FASEB J.
Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation
Br. J. Pharmacol.
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours
Gut
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2
Proc. Natl. Acad. Sci. USA
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
Proc. Natl. Acad. Sci. USA
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer
Cancer Res.
Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels
Anticancer Res.
Somatostatin receptor expression in rat iliac arteries after balloon injury
J. Invest. Surg.
Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5
Proc. Natl. Acad. Sci. USA
Sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells
Cancer Res.
Cited by (102)
Limitations and opportunities in the pharmacotherapy of ciliopathies
2021, Pharmacology and TherapeuticsCitation Excerpt :It also slowed cyst growth and kidney volume expansion with a safety profile similar to that of placebo (Caroli et al., 2013; Perico et al., 2019). Cellularly, somatostatin analogues slow down proliferation and promote apoptosis (Dasgupta, 2004; Ferjoux et al., 2000). The latest analogue named pasireotide was mainly evaluated for polycystic liver disease with a second endpoint on ADPKD.
Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling
2020, Cellular SignallingCystic lesions of the liver—A review
2017, Current Problems in SurgeryCitation Excerpt :Several studies have reported the positive effects of somatostatin analogs in decreasing liver and kidney growth in PKD and ADPLD over a treatment period of a minimum of 6 months.46,77,78,79 Somatostatin may reduce cyst development through several mechanisms: (1) by inhibiting secretin release from the pancreas92,93 by inhibiting secretin-induced cAMP generation and fluid secretion in cholangiocytes,94-96 (2) by vasopressin-induced cAMP generation and water permeability in collecting ducts97-100 by its effects on Gi protein-coupled receptors, and (3) by suppressing the expression of IGF-1, vascular endothelial growth factor, and other cystogenic growth factors and downstreaming signaling from their receptors.97-101 In 2009, van Keimpema and colleagues78 tested lanreotide for treating PLD (120 mg subcutaneously every 4 weeks) for 6 months in 54 patients with PLD (32 ADPKD and 22 ADPLD).
Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives
2023, International Journal of Molecular SciencesRenal ciliopathies: promising drug targets and prospects for clinical trials
2023, Expert Opinion on Therapeutic Targets